Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
AC Immune SA (ACIU)
NASDAQ:ACIU
AC Immune SA (ACIU) Stock Price & Analysis
425 Followers
ACIU Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.20 - $5.14
Previous Close$3.59
Volume230.00K
Average Volume (3M)867.99K
Market Cap
$356.12M
Enterprise Value$273.11M
Total Cash (Recent Filing)CHF78.49M
Total Debt (Recent Filing)CHF3.50M
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Aug 01, 2024EPS Estimate
$0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.69
Shares Outstanding99,197,829
10 Day Avg. Volume271,367
30 Day Avg. Volume867,986
Standard Deviation0.20
R-Squared0.11
Alpha0.00080
Financial Highlights & Ratios
Price to Book (P/B)3.64
Price to Sales (P/S)27.14
Price to Cash Flow (P/CF)-6.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$11.00Price Target Upside206.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
AC Immune SA News
PremiumCompany Announcements
AC Immune SA Announces Major Takeda Partnership
PremiumCompany Announcements
AC Immune SA: Progress and Promise in Neurodegenerative Disease
PremiumCompany Announcements
AC Immune Reports Q1 2024 FinancialsBulls Say, Bears Say
Bulls Say
Clinical Trials And ResearchThe upcoming ACI-24.060 readout is expected to showcase the potential of the treatment, which could significantly de-risk AC Immune's pipeline if safe and measurable plaque removal is observed.
Financial StabilityWith approximately CHF 105M in cash, a $100M payment from Takeda, and an anticipated CHF 25M milestone payment from J&J, AC Immune is well-funded for the next three years.
Strategic PartnershipsThe recent deal with Takeda for the ACI-24.060 program is likely to accelerate development timelines and has validated the treatment approach, increasing confidence in AC Immune's potential.
Bears Say
Research ConcernsThe anti-Tau approach carries higher risk due to ongoing efforts to determine the exact domains of Tau aggregates responsible for toxicity.
RiskThe anti-Tau approach is seen as higher risk as the exact domains of Tau aggregates that drive toxicity are still being determined.
UncertaintyThe exact domains of Tau aggregates that drive toxicity are still being determined, making the anti-Tau approach a higher risk.
---
Ownership Overview
0.00%
Insiders
1.21% Mutual Funds
23.47% Other Institutional Investors
75.32% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ACIU FAQ
What was AC Immune SA’s price range in the past 12 months?
AC Immune SA lowest stock price was $2.20 and its highest was $5.14 in the past 12 months.
What is AC Immune SA’s market cap?
Currently, no data Available
When is AC Immune SA’s upcoming earnings report date?
AC Immune SA’s upcoming earnings report date is Aug 01, 2024 which is in 24 days.
How were AC Immune SA’s earnings last quarter?
AC Immune SA released its earnings results on May 13, 2024. The company reported -$0.199 earnings per share for the quarter, missing the consensus estimate of -$0.149 by -$0.05.
Is AC Immune SA overvalued?
According to Wall Street analysts AC Immune SA’s price is currently Undervalued.
Does AC Immune SA pay dividends?
AC Immune SA does not currently pay dividends.
What is AC Immune SA’s EPS estimate?
AC Immune SA’s EPS estimate is $0.53.
How many shares outstanding does AC Immune SA have?
AC Immune SA has 99,197,830 shares outstanding.
What happened to AC Immune SA’s price movement after its last earnings report?
AC Immune SA reported an EPS of -$0.199 in its last earnings report, missing expectations of -$0.149. Following the earnings report the stock price went up 42.857%.
Which hedge fund is a major shareholder of AC Immune SA?
Among the largest hedge funds holding AC Immune SA’s share is Platinum Investment Management. It holds AC Immune SA’s shares valued at 3M.
---
AC Immune SA Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.00 (206.41% Upside)
$11.00 (206.41% Upside)
Blogger Sentiment
Bullish
ACIU Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 420.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.2%
Last 30 Days ▼ 7.5%
Last 30 Days ▼ 7.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
26.18%
12-Months-Change
Fundamentals
Return on Equity
-37.58%
Trailing 12-Months
Asset Growth
0.31%
Trailing 12-Months
Company Description
AC Immune SA
AC Immune SA is a clinical stage biopharmaceutical company, which engages in developing therapeutic and diagnostic products. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.
---
ACIU Stock 12 Month Forecast
Average Price Target
$11.00
▲(206.41% Upside)
Technical Analysis
Best Analysts Covering ACIU
1 Year
1 Year Success Rate
11/14 ratings generated profit
1 Year Average Return
+13.43%
reiterated a buy rating 2 months ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 78.57% of your transactions generating a profit, with an average return of +13.43% per trade.
---